drugset / Trial / NCT06210360
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
RandomizedParallel-groupOpen-labelTreatment
Summary
This multicentric randomized trial will compare the efficacy and safety of neoadjuvant chemotherapy + surgery + adjuvant chemotherapy or surgery + adjuvant chemotherapy in patients with high-risk resectable pancreatic cancer. NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) will be used as the chemotherapy regimen.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan liposome injection | Unknown | 50 mg/m2 | — |
| Subject | LV | Unknown | 400 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 60 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |